

Promotion 13!



transglutaminase newsletter 3-2012

Ensure your **13% discount** on **13 FXIII-products** for the next **13 days!**

Plasma transglutaminase **Factor XIII** plays an essential role in blood clot formation.

Factor XIII renders the blood clot stiff and resistant against fibrinolytic degradation.

You want to create your own Clotting-Assay to mimic blood clot formation? We provide you with our Transglutaminase specialty reagents to fulfil this task.

	Quantity	Regular Price	Promotion 13 Price
Factor XIII			
• T027 Human blood coagulation Factor XIII	200 µg	350 €	305 €
• T070 Human Factor XIIIa, activated	200 µg	495 €	430 €
Fibrin aggregation and clotting			
• F006 FITC-labelled Fibrinogen	5 mg	195 €	170 €
• F004 Fibrinogen, purified from human plasma	50 mg	95 €	83 €
• T056 Human alpha thrombin, highly active	200 U	175 €	152 €
Fibrin clot degradation			
• P002 Recombinant human plasmin, produced in Yeast	1 mg	395 €	343 €
• P014 Urokinase	1 mg	350 €	305 €
Factor XIII-Inhibitors			
• T101 1,3,4,5-Tetramethyl-2[(2-oxo-propyl)thio]imidazolium chloride	10 mg	455 €	395 €
• T087 Tridegin	200 µg	455 €	395 €
Antibodies			
• A016 Polyclonal antibody to human blood coagulation factor XIII	500 µg	345 €	300 €
• A046 D-Dimer nonoclonal mouse antibody, clone 3B6	100 µg	345 €	300 €
Factor XIII Activity Assays			
• A101 FXIII-Assay Substance, Abz-NE(CAD-DNP)EQVSPLTLK-OH	10 mg	495 €	430 €
• F001 FXIII-Assay Kit	1 Kit	549 €	477 €

The offer is valid from May, **1st** to May **13th**. Just indicate **“Promotion 13”** with your next order.



Already got our new **catalogue 2012?**

Download your electronic copy
or send us an e-mail to receive
your personal hard copy.

Get more information about transglutaminases and Zedira on Facebook  and Twitter  !

For detailed information concerning our products please refer to our web site: www.zedira.com.

Should you have any questions or queries about our products, please do not hesitate to contact us: contact@zedira.com.

We are constantly enlarging our product portfolio in order to fulfill researchers' requirements in the field of transglutaminase.

The newsletter is sent to known interested parties only. If you do not want to receive the Transglutaminase Newsletter anymore, please click here to [unsubscribe](#) your mail address.

In case that you know potential new interested colleagues, please forward this e-mail.

This newsletter is published by:

Zedira GmbH

Roesslerstr. 83

64293 Darmstadt

Germany

Phone: +49 6151 3251-00

Fax: +49 6151 3251-19

Web: www.zedira.com

E-mail: contact@zedira.com

© 2012, Zedira GmbH